Tonix Pharmaceuticals Announces Acceptance of Two Abstracts for Presentation at EULAR
May 26 2015 - 3:45PM
Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) ("Tonix"), a
clinical-stage company developing next-generation medicines for
fibromyalgia, post-traumatic stress disorder, and episodic
tension-type headache, announced today that two abstracts have been
accepted for presentation at the European League Against Rheumatism
Annual Congress (EULAR 2015) in Rome, Italy.
The two accepted abstracts are:
"TNX-102 SL for Treatment of Fibromyalgia: Approaches to Pain
Measurement"
"TNX-102 SL for the Treatment of Fibromyalgia: Role of
Nonrestorative Sleep on Pain Centralization"
About Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals is dedicated to the development of
next-generation medicines for common yet challenging disorders of
the central nervous system, characterized by chronic disability,
inadequate treatment options, high utilization of healthcare
services, and significant economic burden. Tonix's TNX-102 SL is
currently being evaluated in the Phase 3 AFFIRM study in
fibromyalgia and in the Phase 2 AtEase study in post-traumatic
stress disorder. A Phase 2 proof-of-concept study of TNX-201 for
episodic tension-type headache will begin in the second quarter of
2015. To learn more, please visit www.tonixpharma.com.
Cautionary Note on Forward Looking
Statements
Certain statements in this press release are forward-looking
within the meaning of the Private Securities Litigation Reform Act
of 1995. These statements may be identified by the use of
forward-looking words such as "anticipate," "believe," "forecast,"
"estimate" and "intend," among others. These forward-looking
statements are based on Tonix's current expectations and actual
results could differ materially. There are a number of factors that
could cause actual events to differ materially from those indicated
by such forward-looking statements. These factors include, but are
not limited to, substantial competition; our possible need for
additional financing; uncertainties of patent protection and
litigation; uncertainties of government or third party payor
reimbursement; limited research and development efforts and
dependence upon third parties; and risks related to failure to
obtain FDA clearances or approvals and noncompliance with FDA
regulations. As with any pharmaceutical under development, there
are significant risks in the development, regulatory approval and
commercialization of new products. Tonix does not undertake an
obligation to update or revise any forward-looking statement.
Investors should read the risk factors set forth in the Annual
Report on Form 10-K filed with the SEC on February 27, 2015 and
future periodic reports filed with the Securities and Exchange
Commission. All of Tonix's forward-looking statements are expressly
qualified by all such risk factors and other cautionary statements.
The information set forth herein speaks only as of the date
hereof.
TNX-102 SL and TNX-201 are Investigational New Drugs and have
not been approved for any indications.
CONTACT: Tonix Pharmaceuticals Holding Corp.
Leland Gershell
Chief Financial Officer
(212) 980-9155 x104
leland.gershell@tonixpharma.com
Martini Communications
Amy Martini (investors)
amartini@martinicommunications.com
Dian Griesel Int'l.
Susan Forman/Laura Radocaj (media)
(212) 825-3210
sforman@dgicomm.com
lradocaj@dgicomm.com
Tonix Pharmaceuticals (NASDAQ:TNXP)
Historical Stock Chart
From Apr 2024 to May 2024
Tonix Pharmaceuticals (NASDAQ:TNXP)
Historical Stock Chart
From May 2023 to May 2024